Google Answers Logo
View Question
 
Q: Respiratory drug sales figures ( Answered 5 out of 5 stars,   0 Comments )
Question  
Subject: Respiratory drug sales figures
Category: Health > Medicine
Asked by: jkuchta-ga
List Price: $100.00
Posted: 28 Sep 2006 08:54 PDT
Expires: 28 Oct 2006 08:54 PDT
Question ID: 769219
Could you tell me the annual US dollar sales of the brand name drug
Singulair for the past 5 years [2000-2005]?

Also, can you find the Prescription [Rx] sales figures for
non-sedating antihistamines for this same time period vs.
over-the-counter cough and cold drugs?

Request for Question Clarification by bobbie7-ga on 28 Sep 2006 13:47 PDT
Hello Jkuchta, 

I can located the follwoing information:

Singulair sales from 2000-2005

Value of the U.S. over-the-counter cold and cough preparations market 
for 2003, 2005 and 2005

Total value of the U.S. prescription antihistamine market 2001
Market share for Loratidine Allegra and Zyrtec for the same year.
(Allegra is non-sedating)


Estimated value of the US prescription antihistamine market 2002
Retail value of the total US OTC cough, cold and allergy products sector 2002


Value of the market for cough, cold, and allergy remedies in the United States 2001


Would this information be a satisfactory answer to your question?

Bobbie7

Clarification of Question by jkuchta-ga on 29 Sep 2006 06:28 PDT
This information looks like it would suffice, especially for the
Singulair. But, is there any later data than 2001 and 2002 for the
other Rx and OTC data? The more recent we can get our hands on, the
better.

Thank you.

Request for Question Clarification by bobbie7-ga on 29 Sep 2006 08:10 PDT
Jkuchta,

Thank you for your clarification.

I'll resume my search and hopefully I'll locate additional
information. If not, I will post what I have later on today.

Bobbie7

Clarification of Question by jkuchta-ga on 29 Sep 2006 08:39 PDT
Thank you.

Whatever you have as of later today will be fine.
Answer  
Subject: Re: Respiratory drug sales figures
Answered By: bobbie7-ga on 29 Sep 2006 13:04 PDT
Rated:5 out of 5 stars
 
Hello again Jkuchta,

The results of my research are as follows:


Singulair sales 


($ in millions) 

2005     2,975.6
2004     2,622.0
2003     2,009.4

Source:
Merck 2005 Annual Report - Financial Section
http://www.merck.com/finance/annualreport/ar2005/pdf/Merck_2005_Financial_Review.pdf


?Singulair , Merck?s once-a-day leukotriene receptor antagonist
continued its strong performance in 2002 as an asthma controller.
Total 2002 sales of Singulair were $1.5 billion, an increase of 19%
over 2001. Excluding the estimated impact of wholesaler buying
patterns, the year-on-year growth of Singulair approximated 26%.
Worldwide sales of Singulair in 2003 are expected to approximate $2.0
billion to $2.3 billion. Singulair is the No. 1 prescribed asthma
controller among allergists and pediatricians in the United States,
and since its launch in 1998, more than 40 million prescriptions of
Singulair have been dispensed to patients.?


($ in millions) 

2002     1,505.6 
2001     1,268.8 
Hoover?s 
http://www.hoovers.com/free/co/secdoc.xhtml?ID=10986&ipage=2215670


?Total 2002 sales of Singulair were $1.5 billion, an  increase of 19% over 2001.?
Merck Annual Report 2002
http://www.merck.com/finance/annualreport/ar2002/merck_financial_section.pdf


($ in millions) 

2000     $860 million

?Singulair, Merck?s once-a-day leukotriene antagonist, is one of the
top-selling asthma controllers worldwide. Sales in 2000 were $860
million, up 72 percent compared to 1999.?
http://www.anrpt2000.com/access1.htm



?Singulair grew sales 107% in 2001 to $860 million, but the
opportunity is forthcoming as Merck strives for broader usage of the
asthma drug.?
http://www.fool.com/portfolios/rulemaker/2001/rulemaker010821.htm


*************************************************


Value of the U.S. over-the-counter cold and cough preparations market 
for 2003, 2005 and 2005



Year           Cough and cold preparations  
2005           2.6 billion

 ?Cough and cold preparations gain 9.0%, driven by a strong cold and flu season?

Source: (Bar chart on page 7)
Kline & Company
Nonprescription Drugs USA 2005
http://www.klinegroup.com/reports/brochures/cia6d/brochure.pdf


Year           Cough and cold preparations  
2004           2.3 billion

Source: (Bar chart on page 7)
Kline & Company
Nonprescription Drugs USA 2004
http://www.klinegroup.com/reports/brochures/cia6c/brochure.pdf


Year           Cough and cold preparations  
2003           2.25 billion

Source: (Bar chart on page 6)
Kline & Company
Nonprescription Drugs USA 2003
http://www.klinegroup.com/reports/brochures/cia6b/brochure



*************************************************


Value of the market for cough, cold, and allergy remedies in the United States 2001

According to a Kline & Company market research report published
September 2002, the  market for the cough, cold, and allergy remedies
in the United States  was worth about $2.8 billion in 2001.

?The cough, cold, and allergy remedies market continues to grow
modestly while facing increasing competition from prescription
products.?
?Allergy, asthma, and sinus products are predicted to grow by only
1.3% annually, while cough and cold preparations will grow 3% annually
through 2006.?

?Consumers are purchasing more private-label products as a result of
the recession in the last quarter of 2001. Lowerpriced private-label
products will increase their market share but will see diminishing
dollar growth.?

The U.S Cough, Cold, and Allergy Remedies Market 2001
Mindbranch: Market Research Reports
http://www.mindbranch.com/listing/product/R379-0102.html



*************************************************


Total value of the U.S. prescription antihistamine market 2001
Market share for Loratidine Allegra and Zyrtec for the same year.
(Allegra is non-sedating)


 ?Total retail community pharmacy sales of loratadine were $2.25 billion in 2001?

?The total prescription antihistamine market was approximately $4.69
billion for that year, with loratadine accounting for nearly half of
the total.?

?Two other second-generation antihistamines, Allegra and Zyrtec,
accounted for 24.8% and 20.8% of the market, respectively.?

Managed Pharmaceutical Report, March 2003
http://www.rxsolutions.com/c/pbi/pbi_view.asp?docid=322



*************************************************


Estimated value of the US prescription antihistamine market 2002
Retail value of the total US OTC cough, cold and allergy products sector 2002


?Prescription-only antihistamines include Claritin by Schering-Plough,
Alavert by Wyeth, Allegra by Aventis, and Zyrtec by Pfizer. The first
is the best-selling of the three, with all three worth over US$3bn in
prescription sales in 2001.?

"The US prescription antihistamine market is estimated at US$3.8
billion, only US$380 million less than the US$4.2 billion retail value
of the total US OTC cough, cold and allergy products sector.

Euromonitor
OTC Claritin set to have major impact on US market
Date published: 16 Jan 2003
http://www.euromonitor.com/OTC_Claritin_set_to_have_major_impact_on_US_market



*************************************************


Below you will find the additional material I was able to locate today.


US antihistamine market share (September 2002)
See pie chart here:   
http://www.open.imshealth.com/IMSinclude/images/r6a.gif


?Claritin rapidly became the top-selling systemic antihistamine in the
US. According to IMS data, Claritin, Allegra and Zyrtec had combined
US sales of over $3.3 billion in the 12 months to September 2002. By
comparison, Benadryl, the OTC leader with over 40% of the market, had
sales of less than $55 million in the same period, according to IMS
data.?

?In 2002, its clients spent approximately $1.3 billion on non-sedating
antihistamines, including over $600 million on Claritin.?

IMS Health 
http://www.open.imshealth.com/IMSinclude/i_article_20021218.asp
http://www.imshealth.com/web/content/0,3148,64576068_63872702_70261006_70324491,00.html


===========================


Second-Generation Antihistaminas
http://www.pec.ha.osd.mil/Updates/0402web/Mar_04_Update_Page_4.htm


?The newer second-generation antihistamines do not contain
anticholinergics and so do not usually cause drowsiness to the extent
that the first generation antihistamines do. They are then sometimes
referred to collectively as nonsedating antihistamines.?

?The second-generation agents include the following:

Loratadine (Claritin)
Claritin is available over the counter and is approved for children
age two and over.

Desloratadine (Clarinex) is similar to Claritin but significantly more
potent and longer lasting. It is available only by prescription.

Cetirizine (Zyrtec)
Zyrtec is approved for both indoor and outdoor allergies. It is the
only antihistamine to date approved for infants as young as six
months.

Fexofenadine (Allegra). 

Acrivastine (Semprex).? 
Http://adam.about.com/reports/000077_9.htm



===========================


?The allergic rhinitis market ($10.6 billion) is largely made up of
second-generation antihistamines (67%, $6.6 billion), such as Allegra,
Zyrtec, and Clarinex, and intranasal corticosteroids (28%, $2.7
billion), such as Flonase. IMS audits indicate that the US is the
largest market for respiratory products, with sales of $16.0 billion,
representing 63% of worldwide sales.?

Datamonitor Report
Published: Apr-05
http://www.leaddiscovery.co.uk/reports/dmhc2068_rsm.pdf


===========================


The overall oral antihistamine market in 2004 was approximately $3 billion.

Elite Pharmaceuticals, Inc.
Sept. 12, 2006
http://biz.yahoo.com/bw/060912/20060912005933.html?.v=1


===========================


According to a Business Communications Company, Inc. research report,
The U.S. Market for Prescription Allergy Treatment and Management, the
total, U.S. prescription allergy treatment and management market in
2001 generated revenues of $6.45 billion.

?In 2006, this market is forecast to reach $9.6 billion, rising at an
average annual growth rate (AAGR) of 8.3%. ?

?The United States prescription allergy treatment and management
market is divided into four main categories:
antihistamines and combinations 
sympathomimetics, decongestants, and combinations 
corticosteroids 
mast cell stabilizers?

?Growth was sustained by the antihistamines and combinations segment,
mainly from strong sales of Claritin, Allegra, and Zrytec nonsedating
antihistamines.?

The antihistamines and combinations segment will reach over $4 billion in 2006.

----------------------------------------------------------
U.S. Prescription Allergy Products Revenues by Product Type
at U.S. Manufacturers Sales Levels, through 2006 
                                             ($ Billions) 
----------------------------------------------------------
                                      2001         2006
Antihistamines and combinations       2.90         4.01
Sympathomimetics, decongestants 
and combinations                      0.93         1.09
Corticosteroids                       2.28         3.98
Mast cell stabilizers                 0.34         0.52
Total                                 6.45         9.60
----------------------------------------------------------


Bcc Research
The U.S. Market for Prescription Allergy Treatment and Management
Published June 2002
http://www.bccresearch.com/editors/RB-156.html



===========================



Net sales for the years ended December 31, 2005, 2004 and 2003 were as
follows: (Dollars in millions)
                     2005     2004      2003         
CLARINEX/ AERIUS      646      692       694              
CLARITIN Rx(a)        371      321       328                
 

?Global net sales of CLARINEX (marketed as AERIUS in many countries
outside the U.S.), for the treatment of seasonal outdoor allergies and
year-round indoor allergies, decreased $46 million, or 7 percent,
versus 2004. Sales in the U.S. decreased $95 million or 23 percent
versus 2004 due to reduced market share in a declining market. In
September 2005, generic Allegra (fexofenadine) was introduced to the
U.S., which will continue to negatively affect the antihistamine
market including CLARINEX. Sales outside the U.S. increased $49
million or 18 percent to $321 million in 2005 due primarily to market
share gains. Global net sales of CLARINEX were $692 million in 2004,
essentially flat versus 2003. Sales outside the U.S. increased 39
percent to $272 million in 2004 due to market share gains and
continued conversion from prescription CLARITIN. U.S. sales decreased
16 percent to $420 million in 2004 due to the continued contraction in
the U.S. prescription antihistamine market following the launch of OTC
CLARITIN and other branded and non-branded non-sedating antihistamines
coupled with market share declines.?

Form 10-K for SCHERING PLOUGH CORP 
28-Feb-2006
Annual Report
http://biz.yahoo.com/e/060228/sgp10-k.html



===========================


UCB confirms that Zyrtec is the number one most prescribed branded
antihistamine in the US in new prescriptions.


?The US in-market sales of Zyrtec have reached $1,035 million during
the past 9 months ending September 30th, 2005 showing a 10% increase
against the same period in 2004, while the antihistamine market
decreased by 5%.?

?The worldwide sales of Xyzal increased by 26% during the first three
quarters 2005 versus the same period in 2004, confirming its further
market penetration. IMS market share for Xyzal in Europe reached 14%
compared to 12% a year earlier.?

Medical News Today: 26 Oct 2005 
http://www.medicalnewstoday.com/medicalnews.php?newsid=32525


===========================
 

?The cough, cold, allergy, and asthma market is likely to remain the
leading segment in the Rx-to-OTC switched markets. This market will
generate $4.4 billion in sales in 2005, reflecting an average annual
growth rate of 27.8% through the forecast period. This intense growth
is expected to be due to the switching of the leading nonsedating
antihistamines, Claritin and Allegra. With the increasing interest in
self-medication, this market is expected to generate a continued
increase in sales.?

VRG Technologies, Inc.
http://www.vrgtech.com/analysis/rx-to-otc.html


==========================


?In 2004 the OTC cold, flu and allergy remedies market reached an
estimated $2.8 billion in sales, increasing by 5.4% at constant prices
from 1999-2004. This sharp increase is mainly due to the switch of
Schering-Plough?s Claritin to OTC status, after the company?s patent
on loratadine expired. Claritin sold over $290 million in both tablet
and liquid forms in 2003, and dropped slightly to $271.7 million in
2004. Wyeth?s loratadine tablet product, Alavert, sold nearly $59
million in its first year, 2003, and gained slightly in 2004 with
sales of $59.3 million. The combination of these two high-selling
products and the resilience of competing products are the primary
reasons for the sharp increase.?

Research and Markets
http://www.researchandmarkets.com/reportinfo.asp?cat_id=302&report_id=339095&p=1

Pharmalicensing.com
http://pharmalicensing.com/intelligence/reportsearching.php?action=toc&productID=1207023


===========================


Search terms:
non-sedating antihistamines
antihistamine market billion OR million
Singulair sales 
Cough cold medicine OR medications OTC market billion
Over the counter cold cough billion 2000..2006



I hope the information provided is helpful!


Best regards,
Bobbie7

Clarification of Answer by bobbie7-ga on 04 Dec 2006 08:49 PST
The American Lung Association has recently published an Asthma
Medications Chart that might be of your interest.

------------------------------------------
Long-Term Control Medications
------------------------------------------
Generic Name              Brand Name	
------------------------------------------
formoterol fumarate       Foradil Aerolizer

salmeterol xinofate       Serevent Diskus

Budesonide + formeterol   
Fumerate                  Symbicort

Ipratropium bromide
+ albuterol sulfate       Combivent, Duoneb

flucticasone propionate
+ salmeterol xinofate     Advair Diskus

Theophylline              Aerolate III, Aerolate JR
                          Aerolate SR, Choledyl SA
                          Elixophyllin, Quibron- T
                          Quibron - T/SR, Slo-bid
                          Slo-Phyllin, Theo-24
                          Theochron, Theo-Dur, Theolair
                          Theolair SR, T-Phyl, Uni-Dur
                          Uniphyl,

beclomethasone
diaproprionate                        QVAR 40mg, QVAR 80mg

budesonide                Pulmicort Respules
                          Pulmicort Turbuhaler

Flunisolide               AeroBid, Aerospan HFA

fluticasone proprionate   Flovent, Flovent Diskus
                          Flovent HFA

mometasone furoate        Asthmanex

triamcinolone             Azmacort

cromolyn sodium           Intal         
nedocromil sodium         Tilade

zafirlukast               Accolate
zileuton                  Zyflo
montelukast               Singulair
------------------------------------------


------------------------------------------
Quick Relief Medicines
------------------------------------------
Generic Name              Brand Name	
------------------------------------------
albuterol                 Accuneb
                          Proventil HFA
                          Ventolin HFA
albuterol sulfate         ProAir HFA 
                          Proventil Repetabs
                          VoSpire ER 

pirbuterol acetate        Maxair

terbutaline Sulfate       Brethine (tabs only)	

levalbuterol              Xopenex

Levalbuterol tartrate     Xopenex HFA

Ipratropium bromide       Atrovent  	
------------------------------------------
 	 	 	
American Lung Association: October 2006
http://www.lungusa.org/site/pp.asp?c=dvLUK9O0E&b=263990
jkuchta-ga rated this answer:5 out of 5 stars
Excellent, thorough answer

Comments  
There are no comments at this time.

Important Disclaimer: Answers and comments provided on Google Answers are general information, and are not intended to substitute for informed professional medical, psychiatric, psychological, tax, legal, investment, accounting, or other professional advice. Google does not endorse, and expressly disclaims liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in answers or comments. Please read carefully the Google Answers Terms of Service.

If you feel that you have found inappropriate content, please let us know by emailing us at answers-support@google.com with the question ID listed above. Thank you.
Search Google Answers for
Google Answers  


Google Home - Answers FAQ - Terms of Service - Privacy Policy